Inhibikase Therapeutics (IKT) Accumulated Expenses (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Accumulated Expenses for 7 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 11.65% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (up 11.65% YoY), while the FY2025 annual figure was $3.3 million, up 226.5% from the prior year.
• Accumulated Expenses retreated to $2.3 million in Q1 2026 per IKT's latest filing, from $3.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $3.6 million in Q2 2022 and bottomed at $200213.0 in Q1 2022.
• Historically, Accumulated Expenses has averaged $1.4 million across 5 years, with a median of $999303.0 in 2024.
• On a YoY basis, Accumulated Expenses climbed as much as 3461.93% in 2022 and fell as far as 78.08% in 2022.
• Inhibikase Therapeutics' Accumulated Expenses stood at $459997.0 in 2022, then soared by 391.3% to $2.3 million in 2023, then slumped by 55.78% to $999303.0 in 2024, then soared by 226.5% to $3.3 million in 2025, then sank by 30.01% to $2.3 million in 2026.
• Business Quant data shows IKT's Accumulated Expenses at $2.3 million in Q1 2026, $3.3 million in Q4 2025, and $1.2 million in Q3 2025.